Navigation Links
BiOptix announces expansion of Board of Directors
Date:6/27/2012

BOULDER, Colo., June 27, 2012 /PRNewswire/ -- BiOptix announces the appointment of Michael W. Routh, Ph. D. to the Board of Directors of the firm, adding to a preeminent group of leaders driving BiOptix and its proprietary Enhanced Surface Plasmon Resonance platform toward continued success in the life science marketplace.

BiOptix, a leader in the Surface Plasmon Resonance space today announced the appointment of Michael W. Routh, Ph.D. to the Board of Directors.  "The appointment of Dr. Routh brings a wealth of analytical instrument sector knowledge to BiOptix," noted Rick Whitcomb, President and CEO of BiOptix.  "I'm excited to join the Board of Directors of BiOptix—BiOptix has a winning technology value proposition and will continue to exceed customer requirements with its proprietary Enhanced Surface Plasmon Resonance platform.  BiOptix has a world-class team driving the scientific discovery and commercialization process and I'm glad to be a part of this success story," noted Dr. Routh.   

Dr. Routh's career spans over 30 years in the analytical instrument industry split equally between top executive and senior functional leadership roles in such notable companies as Varian, Applied Research Laboratories, Baird, Thermo Fisher Scientific, BioRad and most recently, General Electric.  Dr. Routh earned both B.S. and M.S. degrees at Fresno State University and a Ph.D. degree from the University of Arizona, all in Analytical Chemistry.  

Dr. Routh joins the following individuals on the Board of Directors of BiOptix:

  • William Freytag, Ph.D – Chairman of the Board
  • Kyle Lefkoff – Director
  • Ron Lowy – Director
  • William Marshall, Ph.D – Director
  • Konstantin V. Severinov, Ph.D – Director
  • Sergey Polikarpov – Director
  • Richard Whitcomb – Director, President & CEO, BiOptix

In addition, Dr. Routh will be working with the Management Team of BiOptix:

  • Marty Stanton, Ph.D., Chief Scientific Officer
  • Ken Wilczek, Vice President, Sales & Marketing
  • Nolan Smith, Vice President, Finance
  • Slava Petropavlovskikh, Director, Research & Development, Co-Founder BiOptix

About BiOptix

BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance.  BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com


'/>"/>
SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
2. ChromaDex® Announces Financial Results for the Year Ended 2011
3. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
4. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
5. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
6. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
7. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
8. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
9. Mass. Eye and Ear announces Curing Kids Fund grant recipients
10. Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar
11. BioMed Central announces winners of 6th Annual Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: